CP
CLSD

Castleview Partners’s Clearside Biomedical CLSD Stock Holding History

Castleview Partners’s Portfolio CLSD Stock Details CLSD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-10,797
Closed -$248K – 938
2024
Q1 		$248K Buy
+10,797
New +$233K 0.14% 160

Other funds holding CLSD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Castleview Partners's CLSD Position: Q2 2024 in Review

Castleview Partners sold out of Clearside Biomedical (CLSD) in Q2 2024, closing a stake of 10,797 shares — an estimated $248K sold.

Castleview Partners first reported a position in CLSD in Q1 2024 and held it in 1 quarter. The position peaked at $248K in Q1 2024. 47 funds tracked by Wall St. Rank hold CLSD as of Q2 2024.

  • Castleview Partners reported no remaining Clearside Biomedical position as of Q2 2024 after selling out during the quarter.
  • Castleview Partners sold 10,797 Clearside Biomedical shares in Q2 2024, an estimated $248K.
  • Castleview Partners first reported a position in Clearside Biomedical in Q1 2024 and held it in 1 quarter.
  • Castleview Partners's Clearside Biomedical position peaked at $248K in Q1 2024.
  • 47 funds tracked by Wall St. Rank held Clearside Biomedical as of Q2 2024.

Based on Castleview Partners's 13F filing for Q2 2024, filed 31 Jul 2024.